https://www.tipranks.com/news/the-fly/immunovants-batoclimab-shows-impressive-efficacy-in-mg-says-h-c-wainwright

Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and while H.C. Wainwright analyst Douglas Tsao was encouraged to see the impressive absolute improvements in MG-Activities of Daily Living, the firm acknowledges that the placebo-adjusted readout was mid-pack among FcRn inhibitors-better than nipocalimab but below argenx’s (ARGX) Vyvgart and UCB’s (UCBY) Rystiggo, the analyst tells investors. The company also reported positive initial CIDP results from Period 1 of the study, which showed that following standard of care washout, patients were randomized into 680mg and 340mg batoclimab only, the firm says. The firm has a Buy rating and $51 price target on Immunovant shares, and says the “more is better” debate has not yet been settled.

Light Up your Portfolio with Spark:

Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed  competitor analyses.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on IMVT:

Questions or Comments about the article? Write to [email protected]

Immunovant Announces Positive Phase 3 Study Results Immunovant announces results from Phase 3 study of batoclimab in MG Roivant says Immunovant announces results from Phase 3 study of batoclimab in MG Immunovant’s Phase 3 Trial of Batoclimab: A Catalyst for Future Growth and Market Impact Biohaven price target lowered to $57 from $73 at Bernstein

View Comments